The nation of Zimbabwe has rejected a major American health deal worth $367m (£272m) spanning five years over the United States' insistence on sensitive data.
This rejection came to light after a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government spokesperson has since stated that the US was seeking health data for research and profit but was unwilling to guarantee the resulting advantages from any future treatments.
"We are forced to start the difficult and regrettable process of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged continued negotiations to reach a agreement acceptable to all parties so the country's critical HIV treatment initiative can continue.
Wider Implications
This development comes after a similar situation in Kenya, where a court suspended a related deal with the US following legal challenges were filed about the safety of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had managed assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
As per reports, 16 African countries have so far agreed to similar agreements, constituting over $18.3bn in new funding.
Specifics of the Declined Agreement
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy through US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information over an extended period, with no equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that shared data," he stated.
"Effectively, our country would supply the raw materials for scientific discovery with no assurance that the end products would be accessible to our population should a future pandemic emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending systems previously established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with potential pandemics.
"This framework is designed to guarantee that when a nation contributes its data, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
These objections over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our American counterparts on how subsequent collaboration might be designed in a way that honours the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the government's concerns, but suggested that negotiations should continue since much of the country's HIV programmes depended on international support.
"Where specific concerns exist, such as those involving data governance or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," it said.
The halted deal emphasises the complex tensions between accepting much-needed international aid and protecting a country's data in an increasingly data-driven world.